title: Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.
abstract: BACKGROUND
  Randomized data on statins for primary prevention in older persons are limited, and the relative hazard of cardiovascular disease associated with an elevated cholesterol level weakens with advancing age.
  
  
  OBJECTIVE
  To assess the efficacy and safety of rosuvastatin in persons 70 years or older.
  
  
  METHODS
  Secondary analysis of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), a randomized, double-blind, placebo-controlled trial.
  
  
  METHODS
  1315 sites in 26 countries randomly assigned participants in JUPITER.
  
  
  METHODS
  Among the 17 802 participants randomly assigned with low-density lipoprotein (LDL) cholesterol levels less than 3.37 mmol/L (<130 mg/dL) and high-sensitivity C-reactive protein levels of 2.0 mg/L or more without cardiovascular disease, 5695 were 70 years or older.
  
  
  METHODS
  Participants were randomly assigned in a 1:1 ratio to receive 20 mg of rosuvastatin daily or placebo.
  
  
  METHODS
  The primary end point was the occurrence of a first cardiovascular event (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes).
  
  
  RESULTS
  The 32% of trial participants 70 years or older accrued 49% (n = 194) of the 393 confirmed primary end points. The rates of the primary end point in this age group were 1.22 and 1.99 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio, 0.61 [95% CI, 0.46 to 0.82]; P < 0.001). Corresponding rates of all-cause mortality in this age group were 1.63 and 2.04 (hazard ratio, 0.80 [CI, 0.62 to 1.04]; P = 0.090). Although no significant heterogeneity was found in treatment effects by age, absolute reductions in event rates associated with rosuvastatin were greater in older persons. The relative rate of any serious adverse event among older persons in the rosuvastatin versus placebo group was 1.05 (CI, 0.93 to 1.17).
  
  
  CONCLUSIONS
  Effect estimates from this exploratory analysis with age cut-point chosen after trial completion should be viewed in the context of the overall trial results.
  
  
  CONCLUSIONS
  In apparently healthy older persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin reduces the incidence of major cardiovascular events.
  
  
  BACKGROUND
  AstraZeneca.
authors.affiliation: Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA. rglynn@rics.bwh.harvard.edu
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Glynn
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Koenig
authors.forename: Børge G
authors.initials: BG
authors.lastname: Nordestgaard
authors.forename: James
authors.initials: J
authors.lastname: Shepherd
authors.forename: Paul M
authors.initials: PM
authors.lastname: Ridker
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002097:C-Reactive Protein / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000097:blood / Q000517:prevention & control*; D002423:Cause of Death; D008078:Cholesterol, LDL / Q000097:blood*; D004311:Double-Blind Method; D005260:Female; D005464:Fluorobenzenes / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D011322:Primary Prevention; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D008078:Cholesterol, LDL; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein
references.citation: JAMA. 2004 Apr 21;291(15):1864-70
references.pmid: 15100205
references.citation: Lancet. 2009 Apr 4;373(9670):1175-82
references.pmid: 19329177
references.citation: Lancet. 2005 Oct 8;366(9493):1267-78
references.pmid: 16214597
references.citation: J Am Coll Cardiol. 2006 Dec 5;48(11):2235-42
references.pmid: 17161253
references.citation: PLoS Med. 2007 Aug;4(8):e250
references.pmid: 17683197
references.citation: Lancet. 2002 Nov 23;360(9346):1623-30
references.pmid: 12457784
references.citation: Am J Cardiol. 2007 Oct 1;100(7):1061-7
references.pmid: 17884362
references.citation: N Engl J Med. 2009 Apr 30;360(18):1851-61
references.pmid: 19329822
references.citation: Lancet. 2007 Jan 20;369(9557):168-9
references.pmid: 17240267
references.citation: Lancet. 2008 Jan 12;371(9607):117-25
references.pmid: 18191683
references.citation: Ann Intern Med. 1998 Nov 1;129(9):681-9
references.pmid: 9841599
references.citation: J Clin Oncol. 2009 Apr 1;27(10):1543-4
references.pmid: 19237627
references.citation: BMJ. 1999 Dec 4;319(7223):1492-5
references.pmid: 10582940
references.citation: Lancet. 2007 Dec 1;370(9602):1829-39
references.pmid: 18061058
references.citation: Ann Intern Med. 2009 Feb 17;150(4):243-54
references.pmid: 19221376
references.citation: Heart. 2003 Apr;89(4):417-21
references.pmid: 12639870
references.citation: N Engl J Med. 2008 Nov 20;359(21):2195-207
references.pmid: 18997196
references.citation: Stroke. 2004 Dec;35(12):2902-9
references.pmid: 15514180
references.citation: Clin Trials. 2009 Apr;6(2):119-25
references.pmid: 19342463
references.citation: N Engl J Med. 2002 Nov 14;347(20):1557-65
references.pmid: 12432042
references.citation: Circulation. 2005 Oct 25;112(17):2735-52
references.pmid: 16157765
references.citation: Ann Intern Med. 2001 May 15;134(10):931-40
references.pmid: 11352694
references.citation: N Engl J Med. 1995 Nov 16;333(20):1301-7
references.pmid: 7566020
references.citation: Lancet. 2006 Sep 30;368(9542):1155-63
references.pmid: 17011942
references.citation: Ann Intern Med. 2007 Jul 3;147(1):1-9
references.pmid: 17606955
references.citation: Ann Intern Med. 1997 May 15;126(10):753-60
references.pmid: 9148647
references.citation: JAMA. 1998 May 27;279(20):1615-22
references.pmid: 9613910
references.citation: J Clin Oncol. 2009 Apr 1;27(10):1712-21
references.pmid: 19237631